Cellectis SA
CLLS3.720USD
+0.150+4.20%
交易中 （美東）報價延遲15分鐘
269.05M總市值
虧損本益比TTM
關於 Cellectis SA 公司
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA簡介
公司代碼CLLS
公司名稱Cellectis SA
上市日期Feb 06, 2007
CEOSourdive (David J.D)
員工數量224
證券類型Depository Receipt
年結日Feb 06
公司地址8, rue de la Croix Jarry
城市PARIS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編75013
電話33181691600
網址https://www.cellectis.com/
公司代碼CLLS
上市日期Feb 06, 2007
CEOSourdive (David J.D)
Cellectis SA公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 1月4日 週日
更新時間: 1月4日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
其他
86.98%
持股股東
持股股東
佔比
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
其他
86.98%
股東類型
持股股東
佔比
Investment Advisor
7.72%
Hedge Fund
6.09%
Investment Advisor/Hedge Fund
0.42%
Research Firm
0.22%
其他
85.55%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
74
10.44M
14.44%
-10.92M
2025Q3
77
10.10M
29.65%
-3.45M
2025Q2
79
13.55M
35.05%
-1.95M
2025Q1
82
15.50M
31.47%
-7.25M
2024Q4
86
16.67M
24.79%
+2.93M
2024Q3
104
15.35M
28.39%
+1.55M
2024Q2
103
13.80M
26.34%
-48.27K
2024Q1
112
13.82M
26.53%
-5.23M
2023Q4
124
13.74M
31.43%
+147.34K
2023Q3
142
13.59M
44.11%
-2.54M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Long Focus Capital Management LLC
4.12M
5.7%
-594.03K
-12.59%
Sep 30, 2025
B Group, Inc.
3.28M
4.54%
+25.00K
+0.77%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
BlackRock Institutional Trust Company, N.A.
337.45K
0.47%
+337.45K
--
Dec 31, 2025
Nomura Investment Management Business Trust
226.88K
0.31%
--
--
Sep 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jun 30, 2025
Citadel Advisors LLC
221.96K
0.31%
+221.96K
--
Sep 30, 2025
LPL Financial LLC
85.15K
0.12%
-515.00
-0.60%
Sep 30, 2025
Morgan Stanley & Co. International Plc
83.39K
0.12%
+10.20K
+13.94%
Sep 30, 2025
Millennium Management LLC
57.74K
0.08%
+22.08K
+61.92%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
佔比0%
Avantis International Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
